Mitochondrial dysfunction has been recognized as an early event in Alzheimer's disease (AD) pathology, preceding and inducing neurodegeneration and memory loss. The presence of cytochrome c (CytC) released from the mitochondria into the cytoplasm is often detected after acute or chronic neurodegenerative insults, including AD. The carbonic anhydrase inhibitor (CAI) methazolamide (MTZ) was identified among a library of drugs as an inhibitor of CytC release and proved to be neuroprotective in Huntington's disease and stroke models. Here, using neuronal and glial cell cultures, in addition to an acute model of amyloid beta (Aβ) toxicity, which replicates by intra-hippocampal injection the consequences of interstitial and cellular accumulation of Aβ, we analyzed the effects of MTZ on neuronal and glial degeneration induced by the Alzheimer's amyloid. MTZ prevented DNA fragmentation, CytC release and activation of caspase 9 and caspase 3 induced by Aβ in neuronal and glial cells in culture through the inhibition of mitochondrial hydrogen peroxide production. Moreover, intraperitoneal administration of MTZ prevented neurodegeneration induced by intra-hippocampal Aβ injection in the mouse brain and was effective at reducing caspase 3 activation in neurons and microglia in the area surrounding the injection site. Our results, delineating the molecular mechanism of action of MTZ against Aβ-mediated mitochondrial dysfunction and caspase activation, and demonstrating its efficiency in a model of acute amyloid-mediated toxicity, provide the first combined in vitro and in vivo evidence supporting the potential of a new therapy employing FDA-approved CAIs in AD.
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Introduction
Mitochondrial dysfunction has been associated with neurodegeneration and amyloid β (Aβ 3 ) toxicity in many recent reports (Moreira et al., 2010b; Swerdlow et al., 2010) , and constitutes a valuable therapeutic target for Alzheimer's disease (AD). Mitochondrial pathology and energy metabolism impairment are early events in AD patients and mouse models, preceding the formation of Aβ plaques and memory loss (Atamna and Frey, 2007; Beal, 2005; Moreira et al., 2010a; Santos et al., 2013) . Recent findings in AD mice also revealed reduction in mitochondrial membrane potential (ΔΨ) and the emergence of dystrophic and fragmented mitochondria, as well as increased production of hydrogen peroxide (H 2 O 2 ), with Aβ plaques identified as the source of toxicity (Calkins et al., 2011; Xie et al., 2013) . Apoptotic cell death and caspase-3 activation have been implicated in the pathogenesis of AD. Up-regulation of pro-apoptotic proteins and DNA fragmentation were also found in the AD brain (Smale et al., 1995; Stadelmann et al., 1999) . Our laboratory and others have recently shown that the release of cytochrome c (CytC) is one of the main events linking mitochondrial damage to caspase activation and oligomeric Aβ-mediated apoptotic cell death (Fossati et al., 2010 (Fossati et al., , 2013 Kim et al., 2014) . Mitochondrial deregulation and the presence of CytC in the cytoplasm is often detected after acute or chronic neurodegenerative insults (Friedlander, 2003; Solesio et al., 2013a; Wang et al., 2003; Zhu et al., 2002 Zhu et al., , 2004 . CytC release, through activation of the "apoptosome", induces procaspase 9 
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